Description
ZYLOPRIM® is indicated to reduce the formation of uric acid and urates in conditions in which deposits of these have been presented (gouty arthritis, skin tophi, nephrolithiasis) or there is a predictable clinical risk, for example, when treating certain malignant diseases can cause acute uric acid nephropathy. The main clinical entities in which uric acid or urate deposits can occur are the following:
– Idiopathic gout.
– Uric acid lithiasis.
– Acute uric acid nephropathy.
– Neoplastic disease and myeloproliferative disease with a high degree of cell replacement, in which high levels of urates are present, either spontaneously or after cytotoxic therapy.
– Overproduction of urates caused by certain enzymatic alterations such as: hypoxanthine-guanine-phosphoribosyl-transferase including Lesch-Nyhan syndrome, glucose-6-phosphatase (glycogen storage disease), phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidopho- rhospheres, and phosphoribosylpyrophosphate amidorans -transferase.
ZYLOPRIM® is indicated for the management of renal lithiasis due to 2,8-dihydroxyadenine (2,8-DHA) related to deficient adenine phosphoribosyl transferase activity. Also indicated in the management of mixed recurrent calcium oxalate kidney stones in the presence of hyperuricosuria, when dietary measures, fluid intake, and the like have failed.
Reviews
There are no reviews yet.